What Happened on July 23, 2026
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to discuss several bulk drug substances for possible inclusion on the Section 503A Bulks List.
The committee voted 8-6 with one abstention to recommend that BPC-157 (evaluated for ulcerative colitis) be added to the 503A Bulks List. It also recommended KPV (evaluated for wound healing and inflammatory conditions). These votes are advisory recommendations only. They are not final FDA decisions and do not equal approval of either substance as a finished drug product.
What This Recommendation Does and Does Not Mean
A positive PCAC recommendation can influence the FDA’s eventual decision on these peptides. However, the agency retains final authority. Until FDA takes formal action, the use of compounded BPC-157 and KPV remains subject to existing interim policies and enforcement discretion.
These peptides are not FDA-approved drugs. Any future compounded versions would still require a valid prescription from a licensed clinician and preparation by a pharmacy operating under applicable state and federal rules.
Basic Physiology of the Two Peptides
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide originally derived from a protective protein found in human gastric juice. In laboratory and animal models it has been shown to influence pathways involved in tissue repair, blood-vessel formation (angiogenesis), and gut-barrier integrity. Proposed mechanisms include modulation of growth-factor signaling and reduced local inflammation. Human clinical data remain limited, consisting largely of small or uncontrolled reports rather than large randomized trials.
KPV
KPV is a three-amino-acid fragment (lysine-proline-valine) of the larger hormone alpha-melanocyte-stimulating hormone. It interacts with melanocortin receptors and has demonstrated anti-inflammatory activity in cell and animal models, particularly in settings involving the gut lining and skin. Research interest centers on its ability to dampen certain inflammatory signaling pathways. As with BPC-157, robust human trial evidence is still limited.
Research Context and Practical Considerations
Most published work on both peptides comes from preclinical studies. The limited human observations that exist have not yet established clear efficacy, optimal dosing, or long-term safety. Anyone considering these substances should understand that individual responses can vary.
Medical supervision remains essential. A clinician can review personal health history, potential interactions, and monitoring needs. Laboratory evaluation of related systems—such as hormone status that may influence recovery or inflammation—can form part of a broader clinical picture.
For individuals already working with a clinician on hormone optimization or other peptide protocols, platforms such as Vita Bella offer access to licensed providers who can discuss whether additional options fit within an existing plan.
When recovery from tissue stress or inflammatory issues is under discussion, coordinated review of hormone markers alongside peptide considerations through services like Vita Bella may help align different parts of a treatment approach.
Looking Ahead
The July 23 votes mark a procedural step, not a finished regulatory outcome. Final placement of BPC-157 or KPV on the 503A Bulks List, if it occurs, will depend on subsequent FDA determination. People interested in these compounds should follow official FDA updates and rely on licensed medical guidance rather than informal sources. Careful attention to the actual strength of the evidence remains the most reliable way to evaluate any new option.
References
1. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov. Updated July 2026.
2. Todd S, Lawrence L. In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides. STAT News. July 23, 2026.
3. Eglovitch JS. FDA advisory committee backs two controversial peptides. Regulatory Affairs Professionals Society. July 23, 2026.
4. FDA briefing documents for the July 23, 2026 Pharmacy Compounding Advisory Committee meeting on BPC-157-related and KPV-related bulk drug substances.
